Dr. Aparna Shinde is a final year PhD student in Medicinal Chemistry and Molecular Pharmacology Dept at Purdue University. His PhD thesis is " Role of Tumor Microenvironment in Breast Cancer Metastasis.
Breast Cancer, Extracellular Matrix proteins, Epithelial Mesenchymal Transition, Metastasis, Drug Resistance, Cancer vesicles, ROS production, Nanomaterial Carcinogenesis, lung cancer, Peptides for Cancer Drug Delivery, Nutrition and Cancer
Department of Medicinal Chemistry and Molecular Pharmacology
Purdue University, USA
Dr. Zhenyu Li started his research in biochemistry and cell biology for fighting against diseases such as diabetes and cancer. Later on, he transferred to bio-pharma industry to focus on the development of therapeutic proteins: how to move medicine from bench-top to bedside. With modern process and analysis technology, we are making it real.
Development of Novel Cancer Medicines Especially Therapeutic Protein/Complex for Targeted Therapy.
Dr. Srijita Dhar is a Visiting Fellow in the Section on DNA Helicases under the Laboratory of Molecular Gerontology at the National Institute on Aging, NIH. She received her Masters from the University of Missouri-Columbia, Dept. of Veterinary Pathobiology in 2010. She then received her PhD from the University of Missouri-Columbia, Dept. of Medical Pharmacology and Physiology in 2016. She has published in 9 scientific books and journals, contributed to 5 research projects and attended over 10 international and national conferences. Her work helped in acquiring scientific grants and was also featured in national scientific news.
Dr. Srijita Dhar is interested in Identifying and characterizing Molecular Functions and Biological Pathways that Human DNA Helicases participates in to maintain Genomic Stability. Thereby, investigating RecQ1 and its function in premature aging. Her work also focuses on the Mechanistic role of RecQ and Fe-S helicase in unwinding various DNA substrates using Biochemical assays.
I started education in Cambodia. In 2002, I obtained my degree as Diploma of microbilogy from France. In addition, I pursued my PhD in Hiroshima University in 2011 and graduated in 2016. From 2016, I work there as an independent researcher in Department of Oral and Maxillofacial Pathobiology.
Mr. Marc Antoni Armengol Cubillos has Born in Barcelona in December 1993, interested in science since very young, started studying physics and biotechnology at Universitat de Barcelona (UB) but dropped physics to focus on biological sciences. At same Universitat de Barcelona he studied a Master Degree in translational medicine. During his last year at university he received a Swiss-European Mobility Program (SEMP) Scholarship to fulfill his studies at Université de Genève within the pediatric oncology group under the supervision of Professor Marc Ansari and Dr. Patricia Huezo-Dia. During this period, he focused on single nucleotide polymorphisms in chemotherapy metabolizing genes. He did a short stage (4 months) at Hospital Sant Joan de Déu (Barcelona) in the preclinical pharmacology group under the supervision of Dr. Guillem Pascual where Mr. Marc Antoni focused on exploiting the increased glucose uptake by rhabdomyosarcoma cells to generate a targeted delivery drug system. Currently he is at the Vall d’Hebrón Institut d’Oncología (VHIO) in the experimental hematology group with Dr. Gaël Roué as PI. Mr. Marc Antoni Armengol Cubillos collaborate on different in vitro and in vivo projects mainly focused on searching new therapeutic targets for hematological cancers especially Diffuse Large B Cell Lymphoma.
Anticancer Agents, Apoptosis, Cancer Biology, Carcinogenesis, Molecular & Stem Cell Biology, Drug Discovery & Delivery, Immunotherapy, Molecular Cancer, Onco-Hematology, Resistance and Metastasis, Tumour Microenvironment, Tumour Necrosis, Pediatric Oncology.
Ms. Reham Ajina is a fifth year PhD candidate in the Tumor Biology Program at Georgetown University’s Lombardi Comprehensive Cancer Center. Her goal is to become a leading scientist who conducts pioneering, clinically translatable research in the field of cancer immunology. The first step toward her goal is to obtain a Ph.D degree at an exceptional cancer biology-focused program and to be mentored by a world-expert in the field, which she is currently doing. When she first joined Dr. Louis M. Weiner laboratory for a rotation, she contributed to a project studying how immune selection pressure can manipulate breast cancer epithelial cells at a single cell level, using an unbiased in vivo genome-wide RNAi library. This work led to her inclusion as second author on a paper published in Cancer Immunology, Immunotherapy. Concurrently, Reham published a comprehensive chapter entitled “Cancer Immunotherapy”. After finishing her graduate student rotation, she started her thesis project in the same lab, entitled “Identifying Molecular Determinants of Immune Rejection in Pancreatic Cancer”. Also, Reham has taken the lead in developing two additional projects. First, she has identified that SpCas9-expression by tumor cells cause T cell-dependent tumor rejection in immunocompetent mice, which has led to a first-author paper currently in Press at Oncoimmunology. The second project is focusing on identifying and characterizing cancer neoantigens by advanced computational means. In order to move forward with all these projects, Reham mastered many complicated approaches with creativity and persistence. Also, she has established many collaborations with young investigators as well as with world's leading scientists. In addition, Reham’s intellect is reflected by her academic performance. She obtained her bachelor of science in 2011, where she graduated as valedictorian amongst Medical Laboratory Technology majors. As there is little to no expertise in the field of cancer immunology in her own country, Reham is planning to be a university professor in Saudi Arabia, aiming to share her knowledge and expertise with her future students and colleagues. Driven by her ambition, before finishing her internship, Reham was recruited as a junior faculty by King Saud bin Abdulaziz University for Health Sciences in Saudi Arabia. Indeed, this job offered her full tuition scholarships to pursue her MS and Ph.D degrees. Thus, once Reham completed her bachelor’s degree, she did her Master’s in Biochemistry and Molecular Biology at Georgetown University in 2014, where she again graduated first in her class. Then, she directly joined the Ph.D program in the Tumor Biology department. Furthermore, Reham has done exceptionally well in other areas, including writing, teaching, and poster and oral presentations. In the last three years, Reham has published two papers, a review article, a chapter, and two abstracts. Also, she is currently writing a new first-author manuscript as well as a second review article. While she is enjoying her Ph.D journey, she has also become a wife and mom. Despite the difficulty of creating a balance, with her deep passion for science, she has been able to achieve all these accomplishments.
Cancer Immunology, Pancreatic Cancer and Tumor Biology.
A motivated research scientist with 8 years of R&D experience in
studying cancer risk factor, cancer development, progression and metastases
with specialization in cell assay development, in vivo and ex vivo models,
circulating/disseminated tumor cell research, epigenetics, stem cell
research, and novel therapeutic target discovery.
Breast cancer risk factor, Breast cancer development, progression
and metastases, circulating/disseminated tumor cell research, epigenetics,
stem cell research, and novel therapeutic target discovery.
Dr. Jingjing Chen has been engaged in specialized research in the areas of biochemistry and molecular biology since 2007, beginning with her Ph.D. studies at the Chinese Academy of Sciences, Wuhan Institute of Virology, and as researcher since 2011 at the Stowers Institute for Medical Research in Kansas City, Missouri. She’s currently employed as a Research Specialist working with molecular mechanisms of nuclear membrane remodeling and the molecular mechanism of spontaneous diploidization and its role in the development of cancer. Her research is focused on cell biology with the research direction of understanding the molecular mechanism of centrosome assembly at the nuclear membrane and its function at faithful chromosome segregation in mitosis.
Oncogene Mutation, Cancer Development, Aneuploidy, Immunotherapy
Dr. Gazmend Temaj, born on September. 30th 1974 in Prizren/Kosovo.
1994-2002: Bachelor in General Biology, State University “Hasan prishtina” Prishtina-Kosovo. 2002-2008: Master in Genetics, University of Sarajevo, Faculty of Natural Sciences Bosnia & Herzegovina. 2014-2016: PhD at the Paracelsus Medical University, Salzburg Austria. From 2019 Professor of Molecular Biology and Human/Medical Genetics at the University of Business and Technology, Prishtina Kosovo.
Molecular Biology, Human Genetics, Pharmacogenetics